-- SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.
The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.
The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.
The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.